On BBC Radio 5 Live, Owkin co-founder and CEO Thomas Clozel explains our new AI project to better detect HER2-positive breast cancer
Today our co-founder and CEO Thomas Clozel joined Naga Munchetty on B Radio to discuss our new project to develop hashtag#AI models to better detect HER2-positive breast cancer in women.
About Owkin
Owkin is the first end-to-end AI biotech company on a mission to understand complex biology and ensure every patient gets the right treatment.
We identify precision therapeutics, de-risk and accelerate clinical trials, and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular disease, and immunity and inflammation.
Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across nine cancer indications.
Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like F-Prime, GV and Bpifrance, among others.